Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus

Clinical Cancer Research

Volumn 19, Issue 10, 2013, Pages 2734-2744

  Kanerva, Anna ^a,b   Nokisalmi, Petri ^a   Diaconu, Iulia ^a   Koski, Anniina ^a   Cerullo, Vincenzo ^a   Liikanen, Ilkka ^a   Tähtinen, Siri ^a   Oksanen, Minna ^a   Heiskanen, Raita ^d   Pesonen, Saila ^a   Joensuu, Timo ^c   Alanko, Tuomo ^c   Partanen, Kaarina ^c   Laasonen, Leena ^c   Kairemo, Kalevi ^c   Pesonen, Sari ^a   Kangasniemi, Lotta ^d   Hemminki, Akseli ^a,c,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c International Comprehensive Cancer Center Docrates   (Finland)

^d Oncos Therapeutics   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CGTG 102; CYCLOPHOSPHAMIDE; ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG; CAPSID PROTEIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; ONCOLYTIC VIRUS; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADRENAL CANCER; ADULT; AGED; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; BREAST CANCER; CANCER IMMUNOLOGY; CELL MIGRATION; CELLULAR IMMUNITY; CHILD; COLON CANCER; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ELECTROLYTE DISTURBANCE; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HUMAN; INFLUENZA; KIDNEY CANCER; LEUKOPENIA; LOW DRUG DOSE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MESOTHELIOMA; NEPHROBLASTOMA; NEUROBLASTOMA; OVARY CANCER; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PAROTID GLAND CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; SARCOMA; SCHOOL CHILD; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA; THYROID CANCER; VIRUS CAPSID; VIRUS NEUTRALIZATION; ADENOVIRIDAE; CLASSIFICATION; CLINICAL TRIAL; CLONAL ANERGY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PROCEDURES; SURVIVAL; T LYMPHOCYTE; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADENOVIRIDAE; ADOLESCENT; ADULT; AGED; CAPSID PROTEINS; CHILD; CLONAL ANERGY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; MALE; MIDDLE AGED; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84878074018     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2546     Document Type: Article

References (35)

1. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007;254:178-216.
2. Guo J, Xin H. Chinese gene therapy. splicing out the west? Science 2006;314:1232-5.
3. Johansen P, Storni T, Rettig L, Qiu Z, Der-Sarkissian A, Smith KA, et al. Antigen kinetics determines immune reactivity. Proc Natl Acad Sci U S A 2008;105:5189-94.
4. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010;70:4297-309.
5. Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010;18:1874-84.
6. Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, Escutenaire S, Koski A, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 2011;19:1737-46.
7. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8.
8. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-50S.
9. Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 2012;130:193-47.
10. Nokisalmi P, Pesonen S, Escutenaire S, Sarkioja M, Raki M, Cerullo V, et al. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res 2010;16:3035-43.
11. Pesonen S, Nokisalmi P, Escutenaire S, Sarkioja M, Raki M, Cerullo V, et al. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther 2010;17:892-904.
12. Hemminki O, Bauerschmitz G, Hemmi S, Lavilla-Alonso S, Diaconu I, Guse K, et al. Oncolytic adenovirus based on serotype 3. Cancer Gene Ther 2011;18:288-96.
13. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8:61-70.
14. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anticancer therapy. Cancer Treat Rev 2009;35:553-62.
15. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
16. Kanerva A, Nokisalmi P, Tahtinen S, Koski A, Kangasniemi L, Diaconu I, et al. Serial treatment with oncolytic adenovirus results in redistribution of T-cell subsets in humans and mice. Abstract in ASCGT Annual Meeting. Mol Ther 2012;20:S43. Abstract nr 834.
17. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80:148-58.
18. Koski A, Raki M, Nokisalmi P, Liikanen I, Kangasniemi L, Joensuu T, et al. Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Mol Ther 2012;20:221-9.
19. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008;222:162-79.
20. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial. Lancet Oncol 2008;9:533-42.
21. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validationstudies ontumour assessment. Eur JCancer 2006;42:1031-9.
22. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colonystimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27:5763-71.
23. Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 2005;12:673-81.
24. Bauerschmitz GJ, Guse K, Kanerva A, Menzel A, Herrmann I, Desmond RA, et al. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther 2006;14: 164-74.
25. Sarkioja M, Pesonen S, Raki M, Hakkarainen T, Salo J, Ahonen MT, et al. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Gene Ther 2008;15:921-9.
26. Raki M, Sarkioja M, Escutenaire S, Kangasniemi L, Haavisto E, Kanerva A, et al. Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. J Gene Med 2011;13:253-61.
27. Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002;5:695-704.
28. Hemminki A, Wang M, Desmond RA, Strong TV, Alvarez RD, Curiel DT. Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Hum Gene Ther 2002;13:1505-14.
29. Yu W, Fang H. Clinical trials with oncolytic adenovirus in china. Curr Cancer Drug Targets 2007;7:141-8.
30. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010;17:718-30.
31. Guse K, Cerullo V, Hemminki A. Oncolytic vaccinia virus for the treatment of cancer. Expert Opin Biol Ther 2011;11:595-608.
32. Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: Focus on translational and clinical data. Mol Pharm 2011;8:12-28.
33. Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A, Nemunaitis J. Oncolytic viruses for induction, of anti-tumor immunity. Curr Pharm Biotechnol 2012;13:1750-60.
34. Vera JF, Brenner MK, Dotti G. Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther 2009;9:396-408.
35. Raki M, Sarkioja M, Desmond RA, Chen DT, Butzow R, Hemminki A, et al. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol Oncol 2008;108: 166-72.